CRISPR Therapeutics AG (CRSP) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
CRSP's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CRSP Revenue Analysis (2014–2025)
As of March 2, 2026, CRISPR Therapeutics AG (CRSP) generated trailing twelve-month (TTM) revenue of $36.8 million. The most recent quarter (Q3 2025) recorded $889,000 in revenue.
Looking at the longer-term picture, CRSP's 5-year compound annual growth rate (CAGR) stands at +37.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $913.1 million in 2021.
Revenue diversification analysis shows CRSP's business is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY). Compare CRSP vs ALNY →
Peer Comparison
Compare CRSP's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRSPCurrent | $37M | - | +37.3% | -18933.6% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% | |
| WVE | $108M | +103.7% | +46.6% | -101.9% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.5M | -90.0% | $-92,743,000 | -2642.3% | $-664,571,000 | -18933.6% |
| 2024 | $35.0M | -90.5% | $-75,250,000 | -215.0% | $-466,566,000 | -1333.0% |
| 2023 | $370.0M | +84762.4% | $239.8M | 64.8% | $-222,538,000 | -60.1% |
| 2022 | $436K | -100.0% | $-109,814,000 | -25186.7% | $-673,161,000 | -154394.7% |
| 2021 | $913.1M | +126893.2% | $811.9M | 88.9% | $373.5M | 40.9% |
| 2020 | $719K | -99.8% | $-268,688,000 | -37369.7% | $-354,435,000 | -49295.5% |
| 2019 | $289.6M | +9169.8% | $110.2M | 38.1% | $46.7M | 16.1% |
| 2018 | $3.1M | -92.4% | $-110,649,000 | -3541.9% | $-158,943,000 | -5087.8% |
| 2017 | $41.0M | +693.9% | $-28,803,000 | -70.3% | $-64,648,000 | -157.7% |
| 2016 | $5.2M | +1990.7% | $-37,074,000 | -717.9% | $-68,130,000 | -1319.3% |
See CRSP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRSP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CRSP vs AGIO
See how CRSP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CRSP's revenue growth accelerating or slowing?
CRSP TTM revenue: $37M. YoY growth: N/A. 5-year CAGR: +37.3%.
What is CRSP's long-term revenue growth rate?
CRISPR Therapeutics AG's 5-year revenue CAGR of +37.3% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CRSP's revenue distributed by segment?
CRSP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.